Abstract: A composite article has an increased peel strength and includes a first layer including a low surface energy polymer. The composite article also includes a poly(meth)acrylate layer, an epoxide layer, and a polyurethane elastomer layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an organoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The polyurethane elastomer layer is disposed on and in direct contact with the epoxide layer. The composite article has a 90° peel strength of at least 50 pli measured using ASTM D6862.

Abstract: A composite article has increased pull-off strength and includes a first layer including a low surface energy polymer, a poly(meth)acrylate layer, and an epoxide layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an organoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The epoxide layer includes an epoxide. The composite article has a pull-off strength of greater than zero pli measured using ASTM D4541.

Abstract: A composite article is formed by disposing a poly(meth)acrylate layer, formed as the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, on and in direct contact with a low surface energy polymer layer, disposing an epoxide layer on and in direct contact with said poly(meth)acrylate layer, and disposing a hydrolytically resistant layer on and in direct contact with said epoxide layer. The hydrolytically resistant layer is a hydrolytically resistant polyurethane elastomer that is the reaction product of an aliphatic isocyanate component and an isocyanate-reactive component that retains at least 90% of its initial tensile strength after submersion in standardized seawater for 24 weeks. The isocyanate-reactive component is a hydroxyl-functional polymer having an average hydroxy functionality ranging from 2 to 3, wherein the hydroxyl-functional polymer is a dimer diol, a trimer triol, or a combination thereof.

Abstract: A composite article includes a low surface energy polymer layer, a poly(meth)acrylate layer, an epoxide layer, and a hydrolytically resistant layer. The poly(meth)acrylate layer is disposed on and in direct contact with the low surface energy polymer layer and includes the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, such that the poly(meth)acrylate includes boron. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The hydrolytically resistant layer is disposed on and in direct contact with the epoxide and is the reaction product of an isocyanate component and an isocyanate-reactive component reacted in the presence of a curing agent. The isocyanate-reactive component includes a polydiene polyol and the curing agent crosslinks the carbon-carbon double bonds of the polydiene polyol.

Abstract: A composite article includes a low surface energy polymer layer, a poly(meth)acrylate layer, an epoxide layer, and a hydrolytically resistant layer. The poly(meth)acrylate layer is disposed on and in direct contact with the low surface energy polymer layer and includes the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, such that the poly(meth)acrylate includes boron. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The hydrolytically resistant layer is disposed on and in direct contact with the epoxide and is the reaction product of an isocyanate component and an isocyanate-reactive component reacted in the presence of a curing agent. The isocyanate-reactive component includes a polydiene polyol and the curing agent crosslinks the carbon-carbon double bonds of the polydiene polyol.

Abstract: A composite article is formed by disposing a poly(meth)acrylate layer, formed as the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, on and in direct contact with a low surface energy polymer layer, disposing an epoxide layer on and in direct contact with said poly(meth)acrylate layer, and disposing a hydrolytically resistant layer on and in direct contact with said epoxide layer. The hydrolytically resistant layer is a hydrolytically resistant polyurethane elastomer that is the reaction product of an aliphatic isocyanate component and an isocyanate-reactive component that retains at least 90% of its initial tensile strength after submersion in standardized seawater for 24 weeks. The isocyanate-reactive component is a hydroxyl-functional polymer having an average hydroxy functionality ranging from 2 to 3, wherein the hydroxyl-functional polymer is a dimer diol, a trimer triol, or a combination thereof.

Abstract: A composite article includes a low surface energy polymer layer, a poly(meth)acrylate layer, an epoxide layer, and a hydrolytically resistant layer. The poly(meth)acrylate layer is disposed on and in direct contact with the low surface energy polymer layer and includes the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, such that the poly(meth)acrylate includes boron. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The hydrolytically resistant layer is disposed on and in direct contact with the epoxide and is the reaction product of an isocyanate component and an isocyanate-reactive component reacted in the presence of a curing agent. The isocyanate-reactive component includes a polydiene polyol and the curing agent crosslinks the carbon-carbon double bonds of the polydiene polyol.

Abstract: A composite article has an increased peel strength and includes a first layer including a low surface energy polymer. The composite article also includes a poly(meth)acrylate layer, an epoxide layer, and a polyurethane elastomer layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an or -ganoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The polyurethane elastomer layer is disposed on and in direct contact with the epoxide layer. The composite article has a 90° peel strength of at least 50 pli measured using ASTM D6862.

Abstract: A composite article has increased pull-off strength and includes a first layer including a low surface energy polymer, a poly(meth)acrylate layer, and an epoxide layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an organoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The epoxide layer includes an epoxide. The composite article has a pull-off strength of greater than zero pli measured using ASTM D4541.

Abstract: The present invention is a method for treating uterine fibroid disease using a compound of formula I wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C4-C6 alkyl); R2 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl) or —OSO2(C4-C6 alkyl); n is 2 or 3; and R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Abstract: The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.

Abstract: The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —O—, —CH2—, or —C(O)—; X1 is —O— or —NR2—; R2 is —H or —CH3; Y is —S—, —CH2CH2—, or —HC?CH—; m is 0, 1, 2, or 3; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Abstract: What is disclosed are growth hormone secretagogues, and their uses, of formula (I) wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: A compound of the formula 1

Abstract: A compound of the formula or a pharmaceutically acceptable salt or solvate thereof. Also provided by the invention are methods of use of the above compounds, and processes for the preparation thereof.

Abstract: The present invention provides novel, reduced benzothiophenes of formula I wherein R is —H, —OH, —O(C1-C4 alkyl), —O—CO—(C1-C6 alkyl), —O—CO—Ar in which Ar is optionally substituted phenyl, or —O—SO2—(C4-C6 alkyl); R1 is —H, —OH, —O(C1-C4 alkyl), —O—CO—(C1-C6 alkyl), —O—CO—Ar in which Ar is optionally substituted phenyl, —O—SO2—(C4-C6 alkyl) chloro or bromo; n is 2 or 3; and R2 and R3 each are independently C1-C4 alkyl, or combine to form 1-piperidinyl, 1-pyrrolidino, methyl-1-pyrrolidino, dimethyl-1-pyrrolidino, 4-morpholino or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Further provided are methods for alleviating the symptoms of post-menopausal syndrome, and inhibiting endometriosis, uterine fibrosis, and aortal smooth muscle cell proliferation.

Abstract: The instant invention provides novel benzothiophene compounds for use in treating skeletal diseases.

Abstract: This invention relates to the fields of pharmaceutical and organic chemistry and provides novel phosphorous-containing benzothiophene compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus and cervix. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.